A Phase 2 interventional study of Aramchol in Fatty Liver, Non-Alcoholic Steatohepatitis and Liver Diseases, sponsored by Galmed Research and Development, Ltd.. Completed at 78 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-14.
Sponsored by Galmed Research and Development, Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 211 studies in Fatty Liver with a site in United States — 41 open to participants now, 47 under way, 8 of them phase 3. Fatty Liver · United States.
Among the 211 studies in Fatty Liver with a site in United States, this one is the 14th largest by enrollment of the 162 interventional ones that give a count, is one of 10 that started in 2015, is one of 43 in phase 2, and was the 78th registered.
663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.
Browse Fatty Liver studies →41 of the 211 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Kriya Therapeutics, Inc. · Sites in United States, New Zealand
Ages 18–75
Altimmune, Inc. · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
211 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 57 · Phase 3 17 · Phase 4 12
First in 2001; this study’s year is marked. 10 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 247 is above the median of 60 across 432 interventional studies indexed under Fatty Liver.
Median enrollment 45 across the 162 interventional studies, 85 across the 48 observational. Of the 149 that completed or were terminated, 63 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 211 have an industry lead sponsor. The 10 most frequent:
Galmed Research and Development, Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Galmed Research and Development, Ltd. has 1 study filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
13 of the studies in Fatty Liver with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06354088Columbia UniversityHuman Models of Selective Insulin Resistance: Alpelisib, Part I | 2026-12-31 |
| NCT04781322National Institute on Alcohol Abuse and Alcoholism (NIAAA)Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers | 2026-12-31 |
| NCT06944353Northwestern UniversityImproving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED | 2027-01 |
| NCT07491458Rivus Pharmaceuticals, Inc.A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) | 2027-02 |
| NCT07495332Duke UniversitySiemens Biomarker Multi-modality | 2027-05 |
Add all 13 to your calendar (.ics) → With an account.
Among the 211 studies in Fatty Liver with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, Phase IIb, randomized, double blind, placebo-controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects that are 18 to 75 years of age, with Non-Alcoholic Steatohepatitis (NASH) confirmed by liver biopsy performed in a period of 6 months before entering the study, with overweight or obesity and who are pre diabetic or type II diabetic.
Eligible subjects will be enrolled into three treatments arms: Aramchol 400 and 600 mg tablets and placebo tablets in ratio 2:2:1.
The subjects will be evaluated at study sites for 11 scheduled visits during one year (52 weeks). After completion of the study treatment period, the subjects will be followed for an additional period of 13 weeks without study medication (until visit 11 (week 65)).
This is a multicenter, Phase IIb, randomized, double blind, placebo-controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects that are 18 to 75 years of age, with Non-Alcoholic Steatohepatitis (NASH) confirmed by liver biopsy performed in a period of 6 months before entering the study, with overweight or obesity and who are pre diabetic or type II diabetic.
Eligible subjects will be enrolled into three treatments arms: Aramchol 400 and 600 mg tablets and placebo tablets in ratio 2:2:1.
The subjects will be evaluated at study sites for 11 scheduled visits: at screening (visit 1(weeks -4 - 0)), baseline (visit 2 (day 0)), visit 3 (week 2), visit 4 week 4), visit 5 (week 8), visit 6 (week 12), visit 7 (week 24), visit 8 (week 32), visit 9 (week 40) and visit 10 (week 52 - (End of Treatment/early termination visit)). After completion of the study treatment period, the subjects will be followed for an additional period of 13 weeks without study medication (until visit 11 (week 65)).
During the screening period, the severity of the disease will be evaluated with blood tests, liver biopsy and NMRS.
During the study the following assessments will be performed:
The following blood tests will be performed: complete blood count (CBC), serum chemistry (including electrolytes, liver enzymes, direct and total bilirubin, glucose, lipid profile which include triglyceride, cholesterol, HDL, LDL and VLDL, CPK, creatinine, urea, albumin, alkaline phosphatase), ESR and urinalysis during the screening visit, baseline, week 2, 4, 8, 24, 40, 52 and 65 (end of follow up) visits. Serology (HBV, HCV and HIV) will be performed during the screening visit. Coagulation (fibrinogen, PT/INR, aPTT) will be measured during screening and at baseline, week 24, End of Treatment/early termination and week 65 visits. Insulin (HOMA) will be measured during the screening, at week 24 and End of Treatment/early termination visits. HbA1C will be measured during the screening, at week 8, 24, 40 and End of Treatment/early termination visits. C reactive protein, Leptin and Adiponectin will be measured during baseline visit and at end of treatment period. The blood samples taken at these visits, will be tested for possible biomarkers. TSH, T3 and T4 will be measured during the screening visit. beta-hCG in women of childbearing potential will be performed during the screening visit. A serum sample will be collected and kept frozen until study end in case special investigation needs to be performed. This sample will be collected during the screening and visit 10/Early Termination.
Safety assessment will include frequency and severity of treatment-emergent AEs, clinically significant laboratory abnormalities, ECG changes and physical examination findings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treatment with other anti-diabetic medications:
GLP-1 receptor agonists and Thiazolidinediones (TZDs), unless started at least 12 months prior to biopsy and on stable dose for 6 months. In case of GLP-1 receptor agonists stopped, it should be at least 6 months before biopsy as per medical history.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
Drug: Aramchol
One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.
Drug: Aramchol
Two tablet of Aramchol matching placebo.
Drug: Aramchol
Subjects will be administered Aramchol as follows: * One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol. * One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg. * Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml). Subjects are allowed to omit study drugs up to 3 consecutive days during the study.
Also known as: Placebo
Change From Baseline in Mean Liver Fat
absolute % change from baseline to end of study in liver triglycerides to water ratio (fat/water+fat) as measured by MRS
Time frame: At screening (baseline) and at week 52
NASH Resolution Without Worsening of Fibrosis
The endpoint was defined as end of study biopsy, observed under microscope and showing: * Cell Ballooning (special form of liver cell injury associated with cell swelling and enlargement)= 0 * Inflammation (presence or absence of cells from the immune system) = 0 or 1 * No worsening of fibrosis (scar formation) = increase in fibrosis score by 1 or more point
Time frame: At screening and at week 52
Fibrosis Improvement Without Worsening of NASH
The endpoint was defined as end of study biopsy showing: * A decrease in fibrosis score ≥ 1 point * No worsening of NASH (defined by an increase of inflammation and/or ballooning)
Time frame: At screening and at week 52
Change From Baseline to Week 52/Termination in ALT
Change from baseline to Week 52 or Termination visit in ALT levels (U/L)
Time frame: At baseline until week 52
Change From Baseline to Termination/Early Termination in HbA1C
Change from baseline to Week 52 or Termination visit in Hemoglobin A1C (%)
Time frame: At baseline until week 52
| Milestone | Aramchol 600mg | Aramchol 400mg | Placebo |
|---|---|---|---|
| Started | 98 | 101 | 48 |
| Completed | 88 | 90 | 41 |
| Not completed | 10 | 11 | 7 |
| Withdrew: Withdrawal by subject | 3 | 6 | 3 |
| Withdrew: Adverse event | 4 | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Disallowed medication | 1 | 1 | 2 |
| Withdrew: Bariatric surgery | 1 | 0 | 0 |
absolute % change from baseline to end of study in liver triglycerides to water ratio (fat/water+fat) as measured by MRS
| Abs. % Change from Baseline Liver Fat | Aramchol 600mg | Aramchol 400mg | Placebo |
|---|---|---|---|
| Change From Baseline in Mean Liver Fat | -3.18 ± 1.01 | -3.41 ± 0.96 | -0.09 ± 1.38 |
The endpoint was defined as end of study biopsy, observed under microscope and showing: * Cell Ballooning (special form of liver cell injury associated with cell swelling and enlargement)= 0 * Inflammation (presence or absence of cells from the immune system) = 0 or 1 * No worsening of fibrosis (scar formation) = increase in fibrosis score by 1 or more point
| % of subjects reaching the end-point | Aramchol 600mg | Aramchol 400mg | Placebo |
|---|---|---|---|
| NASH Resolution Without Worsening of Fibrosis | 16.7 | 7.5 | 5 |
The endpoint was defined as end of study biopsy showing: * A decrease in fibrosis score ≥ 1 point * No worsening of NASH (defined by an increase of inflammation and/or ballooning)
| % of subjects reaching the end-point | Aramchol 600mg | Aramchol 400mg | Placebo |
|---|---|---|---|
| Fibrosis Improvement Without Worsening of NASH | 29.5 | 21.3 | 17.5 |
Change from baseline to Week 52 or Termination visit in ALT levels (U/L)
| U/L | Aramchol 600mg | Aramchol 400mg | Placebo |
|---|---|---|---|
| Change From Baseline to Week 52/Termination in ALT | -17.3 ± 3.7 | -12.0 ± 3.6 | 11.8 ± 5.2 |
Change from baseline to Week 52 or Termination visit in Hemoglobin A1C (%)
| % of HbA1C | Aramchol 600mg | Aramchol 400mg | Placebo |
|---|---|---|---|
| Change From Baseline to Termination/Early Termination in HbA1C | -0.1268 ± 0.0769 | -0.0417 ± 0.0754 | 0.3202 ± 0.1089 |
Change from baseline to Week 52 or termination visit in AST levels (U/L)
| U/L | Aramchol 600mg | Aramchol 400mg | Placebo |
|---|---|---|---|
| Change From Baseline to Week 52/Termination in AST | -10.83 ± 2.49 | -7.21 ± 2.42 | 6.68 ± 3.50 |
A responder is defined according to \>5% absolute improvement from baseline. A cutoff of 5% absolute reduction in liver F/(F+W) ratio was used as a surrogate for potentially clinically meaningful MRI reduction.
| percentage of participants | Aramchol 600mg | Aramchol 400mg | Placebo |
|---|---|---|---|
| Change From Baseline in Mean Liver Fat - Responder Analysis | 47.0 | 36.7 | 24.4 |
Fibrosis stage 4 in liver biopsy
| Participants | Aramchol 600mg | Aramchol 400mg | Placebo |
|---|---|---|---|
| Progression to Cirrhosis | 1 | 6 | 3 |
Collected over 52 weeks + 13 weeks follow-up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aramchol 600mg | 0/98 (0%) | 9/98 (9.2%) | 77/98 (78.6%) |
| Aramchol 400mg | 0/101 (0%) | 9/101 (8.9%) | 75/101 (74.3%) |
| Placebo | 0/48 (0%) | 6/48 (12.5%) | 33/48 (68.8%) |
| Event | Aramchol 600mg | Aramchol 400mg | Placebo |
|---|---|---|---|
| Bile duct stoneHepatobiliary disorders | 0/98 | 0/101 | 1/48 |
| Retinal detachmentEye disorders | 0/98 | 0/101 | 1/48 |
| CholecystitisHepatobiliary disorders | 0/98 | 0/101 | 1/48 |
| Abscess limbInfections and infestations | 0/98 | 0/101 | 1/48 |
| Mammogram abnormaInvestigations | 0/98 | 0/101 | 1/48 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/98 | 0/101 | 1/48 |
| Gallbladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/98 | 0/101 | 1/48 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/98 | 0/101 | 1/48 |
| MyelofibrosisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/98 | 0/101 | 1/48 |
| Abdominal wall haematomaGastrointestinal disorders | 1/98 | 0/101 | 0/48 |
| Event | Aramchol 600mg | Aramchol 400mg | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 15/98 | 14/101 | 6/48 |
| Urinary tract infectionRenal and urinary disorders | 13/98 | 15/101 | 3/48 |
| ConstipationGastrointestinal disorders | 8/98 | 5/101 | 6/48 |
| NauseaGastrointestinal disorders | 9/98 | 10/101 | 6/48 |
| PruritusSkin and subcutaneous tissue disorders | 10/98 | 7/101 | 2/48 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/98 | 4/101 | 4/48 |
| FatigueGeneral disorders | 3/98 | 8/101 | 4/48 |
| InfluenzaRespiratory, thoracic and mediastinal disorders | 5/98 | 8/101 | 2/48 |
| Abdominal painGastrointestinal disorders | 4/98 | 7/101 | 2/48 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/98 | 7/101 | 1/48 |
| Age, Continuous(years) | Aramchol 600mg | Aramchol 400mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 54.9 ± 9.8 | 53.9 ± 10.9 | 54.4 ± 10.3 | 54.4 ± 10.3 |
| Sex: Female, Male(Participants) | Aramchol 600mg | Aramchol 400mg | Placebo | Total |
|---|---|---|---|---|
| Female | 70 | 65 | 25 | 160 |
| Male | 28 | 36 | 23 | 87 |
| Race/Ethnicity, Customized(Participants) | Aramchol 600mg | Aramchol 400mg | Placebo | Total |
|---|---|---|---|---|
| Asian | 5 | 4 | 1 | 10 |
| Black or African American | 1 | 0 | 1 | 2 |
| Hispanic | 12 | 17 | 11 | 40 |
| Latin | 16 | 14 | 3 | 33 |
| Latin American | 1 | 1 | 1 | 3 |
| Latin Race | 0 | 1 | 1 | 2 |
| Mixed (Martinican) | 0 | 1 | 0 | 1 |
| White | 63 | 63 | 30 | 156 |
| BMI (kg/m^2) at Screening(kg/m^2) | Aramchol 600mg | Aramchol 400mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 33 ± 4.2 | 32.4 ± 4.5 | 32.6 ± 4.9 | 32.7 ± 4.4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2015 to primary completion in May 2018, 36 months.
Results were first posted in Jul 2021, 3 years 1 month after primary completion.
Of 41 phase 2 interventional studies under Fatty Liver, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's 36 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aramchol
Galmed Research and Development, Ltd.